Donate Tissue

Month: January 2024

  • Endeavour Cells investment in Cell2Cure

    Endeavour Cells investment in Cell2Cure

    Cell2Cure has January 2024 received a significant equity investment from Endeavour Cell ApS, to further develop our collaboration.

    Endeavour Cells will own 51% of the company. In addition to the invested capital the collaboration with Endeavor Cells includes milestone payments and potential continued financing of Cell2Cure’s activities within a 5-year time frame.

    This collaboration will further consolidate Cell2Cure and strengthen the technological, clinical and commercial development of our very promising stem cell treatment technology.

    The overall goal for Cell2Cure is to establish stem cells as a new treatment option for several disease indications for the benefit of the patients and the society.

    Press release (in danish)

  • Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    Cell2Cure is partner in an EU-funded project, RESTORE VISION, within rare eye diseases

    In Europe, approximately 30 million people suffer from blindness and visual impairment. Rare Eye Diseases are a major cause that can result in blindness in children and young adults and affect adults and the ageing population. Current management is expensive, has low efficacy, and significant side effects.

    The consortium – RESTORE VISION – aims to address this clinical need by formulating novel treatments and repurposed drugs that have been validated in different disease indications (Home – Restore vision).

    The project will target seven rare eye diseases: aniridia-associated keratopathy; neurotrophic keratopathy; limbal stem cell deficiency; ocular cicatricial pemphigoid; EEC syndrome; ocular graft versus host disease; and corneal neovascularisation.

    Cell2Cure participate in the consortium with the patented cell product: allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) and our expertise within conduction of clinical trials.

    The ASC products will be tested in a clinical trial as an immunosuppressive treatment in patients with ocular graft versus host disease.